FDA 483 - Scientific Pharmaceuticals, Inc. - January 09, 2020

An FDA inspection of Scientific Pharmaceuticals, Inc. in Pomona, CA, a medical device manufacturer, revealed significant deficiencies in design control documentation. Observations included inadequate documentation of design input requirements for a Class II medical device and a lack of documented design risk analysis results. These issues indicate a failure to properly establish and maintain design controls for new product development.